What is DaVita Inc. (DVA) DCF Fair Value and Intrinsic Value in 2026?

DaVita Inc. (DVA) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is DaVita Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

DaVita Inc. operates in the Healthcare sector (Medical Care Facilities) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is DaVita Inc.'s financial health rating and Piotroski F-Score?

DaVita Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor DaVita Inc. (DVA) for quarterly SEC filing thesis breaks?

LocalAlpha audits DaVita Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksDVA

DVA

DaVita Inc.Healthcare / Medical Care FacilitiesINTACT

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Share Price

$182.38

52W: $101 - $247.49

DCF Fair Value

$148.22

-23% Premium

Thesis Hub

P/E (TTM)

15.5x

ROIC

12.1%

Operating Margin

16.1%

FCF Yield

8.9%

Debt / Equity

12.42x

Piotroski Score

8/9

Altman Z-Score

3.77

Market Cap

$11.7B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($148.22)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$148.22

MOS Buy Target (-25%)

$111.17

Valuation Overlays: DCF Fair Value ($148.22) 25% MOS Buy Target ($111.17) Revised Graham ($222.82)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$182.38

DCF Fair Value

$149.42

-22.1% Premium

Starting Free Cash Flow ($M)$1,042M

$100M$1,042M (Reported)$50,000M

Stage 1 Growth (Years 1-5)8.1%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$12,700M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$9.5B

PV of Terminal Value

$12.8B

Implied Enterprise Value

$22.3B

Implied Equity Value

$9.6B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$1,126	$1,218	$1,316	$1,423	$1,538	$1,607	$1,680	$1,755	$1,834	$1,917
Present Value (PV)	$1,033	$1,025	$1,016	$1,008	$1,000	$958	$919	$881	$845	$810

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number

N/A

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

Not calculable here: the formula takes a square root of EPS × book value, so it breaks down when trailing earnings (or book value) are negative. A company losing money has no defensive-investor price under Graham's classic test — lean on the DCF and solvency scores instead.

EPS: $11.80BVPS: $-11.96

Revised Graham Formula+18.1%

$222.82

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings8.5% Yield

$15.47 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $1.0BYield: 8.5%

Reverse DCF: Market Growth Expectation

EXTREMELY LOW BARRIER

-2.1% CAGR (Next 10 Yrs)

At the current price of $182.38, the market is assuming the business will compound Free Cash Flow at -2.1% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

✓ Low market hurdle: Easy for a wide-moat compounder to beat.

Autonomous Thesis Underwriting

Surveil DVA with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for DaVita Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 16.1% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track DVA & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: DaVita Inc. (DVA) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for DaVita Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, DaVita Inc. has an estimated DCF intrinsic fair value of $148.22 per share compared to its current market price of $182.38. This represents an estimated 23.0% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $N/A.